Search results
Results From The WOW.Com Content Network
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. [6] [7] [8] [4] It is also used for the treatment of eosinophilic esophagitis, [9] prurigo nodularis [10] and ...
macular degeneration (wet form) Raxibacumab [39] mab: human: anthrax toxin, protective antigen: Y: anthrax (prophylaxis and treatment) Ravagalimab [5] mab: humanized: CD40: Crohn's disease Ravulizumab [26] Ultomiris: mab: humanized: C5: Y: paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome: Refanezumab: mab: humanized ...
(Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the ...
Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the ...
After a request comes in from a qualified provider, the request will go through the prior authorization process. The process to obtain prior authorization varies from insurer to insurer but typically involves the completion and faxing of a prior authorization form; according to a 2018 report, 88% are either partially or entirely manual.
Express Scripts Holding Company is a pharmacy benefit management (PBM) organization. In 2017 it was the 22nd-largest company in the United States by total revenue as well as the largest pharmacy benefit management (PBM) organization in the United States. [2]
Rank Brand Name(s) Generic Name Sales Q1 2014 Sales ($000) Change from Q4 2013 Company(ies) Disease/Medical Use First Approval Date Patent Expiration Date [6] [7]; 1: Abilify
F1000 (formerly "Faculty of 1000") is an open research publisher for scientists, scholars, and clinical researchers. F1000 offers a different research evaluation service from standard academic journals by offering peer-review after, rather than before, publishing a research article. [ 1 ]